- Home
- PMF vs NBTX Comparison
PMF vs NBTX Comparison
Compare PMF & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMF
- NBTX
- Stock Information
- Founded
- PMF 2001
- NBTX 2003
- Country
- PMF United States
- NBTX France
- Employees
- PMF N/A
- NBTX N/A
- Industry
- PMF Finance/Investors Services
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- PMF Finance
- NBTX Health Care
- Exchange
- PMF Nasdaq
- NBTX Nasdaq
- Market Cap
- PMF 249.4M
- NBTX 235.6M
- IPO Year
- PMF N/A
- NBTX 2020
- Fundamental
- Price
- PMF $10.08
- NBTX $5.08
- Analyst Decision
- PMF
- NBTX Strong Buy
- Analyst Count
- PMF 0
- NBTX 2
- Target Price
- PMF N/A
- NBTX $11.50
- AVG Volume (30 Days)
- PMF 61.3K
- NBTX 13.3K
- Earning Date
- PMF 01-01-0001
- NBTX 10-15-2024
- Dividend Yield
- PMF 5.36%
- NBTX N/A
- EPS Growth
- PMF N/A
- NBTX N/A
- EPS
- PMF N/A
- NBTX N/A
- Revenue
- PMF N/A
- NBTX $45,220,186.00
- Revenue This Year
- PMF N/A
- NBTX N/A
- Revenue Next Year
- PMF N/A
- NBTX N/A
- P/E Ratio
- PMF N/A
- NBTX N/A
- Revenue Growth
- PMF N/A
- NBTX 526.17
- 52 Week Low
- PMF $7.69
- NBTX $4.14
- 52 Week High
- PMF $10.56
- NBTX $8.96
- Technical
- Relative Strength Index (RSI)
- PMF 61.85
- NBTX 44.15
- Support Level
- PMF $10.03
- NBTX $4.93
- Resistance Level
- PMF $10.14
- NBTX $5.36
- Average True Range (ATR)
- PMF 0.13
- NBTX 0.34
- MACD
- PMF -0.01
- NBTX -0.01
- Stochastic Oscillator
- PMF 43.34
- NBTX 17.80
About PMF PIMCO Municipal Income Fund
PIMCO Municipal Income Fund is a closed-end management investment company. Its primary investment objective is to seek to provide current income exempt from federal income tax. The fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal income tax.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.